PMID- 26161550
OWN - NLM
STAT- MEDLINE
DCOM- 20160408
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 7
DP  - 2015
TI  - The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere 
      Copy Number in HER2 Fish Equivocal Breast Carcinomas.
PG  - e0132824
LID - 10.1371/journal.pone.0132824 [doi]
LID - e0132824
AB  - Chromosome 17 centromere (CEP17) gain is frequently observed in breast cancer by 
      fluorescence in situ hybridization (FISH). To address the biologic 
      characteristics and clinical significance of CEP17 gain in a large population of 
      breast cancer patients, we performed FISH on a series of 770 breast cancer 
      tissues to evaluate the status of human epidermal growth factor receptor 2 (HER2) 
      gene and CEP17 by immunohistochemistry (IHC) and FISH. Among the 770 specimens, 
      184 cases showed CEP17 gain (23.9%). Histological grade, nodal status, HER2 by 
      IHC, Ki 67 index, and p53 expression were significantly different between CEP17 
      gain tumors and HER2-positive tumors. In contrast with HER2-negative tumors, 
      CEP17 gain tumors showed higher histological grade, higher HER2 score by IHC, and 
      higher Ki 67 index. The patients with CEP17 gain tumors had an intermediate 
      survival between HER2-negative and HER2-positive patients. By comparison to 
      HER2-negative and HER2-positive patients, survival in luminal B patients with 
      CEP17 gain tumors also fell in between. In conclusion, CEP17 gain tumors show 
      specific differences compared with HER2-negative and HER2-positive tumors in 
      clinical parameters and prognosis.
FAU - Ji, Hongfei
AU  - Ji H
AD  - Department of Cancer Molecular and Biology, Cancer Institute of Harbin Medical 
      University, Harbin, China.
FAU - Xuan, Qijia
AU  - Xuan Q
AD  - Department of Medical Oncology, Tumor Hospital of Harbin Medical University, 
      Harbin, China.
FAU - Nanding, Abiyasi
AU  - Nanding A
AD  - Department of Pathology, Tumor Hospital of Harbin Medical University, Harbin, 
      China.
FAU - Zhang, Haiyu
AU  - Zhang H
AD  - Department of Biostatistics, Harbin Medical University, Harbin, China.
FAU - Zhang, Qingyuan
AU  - Zhang Q
AD  - Department of Cancer Molecular and Biology, Cancer Institute of Harbin Medical 
      University, Harbin, China; Department of Medical Oncology, Tumor Hospital of 
      Harbin Medical University, Harbin, China.
LA  - eng
PT  - Journal Article
DEP - 20150710
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/*genetics/metabolism/mortality
MH  - Carcinoma, Ductal, Breast/*genetics/metabolism/mortality
MH  - Centromere/*genetics
MH  - Chromosomes, Human, Pair 17/*genetics
MH  - DNA Copy Number Variations
MH  - Disease-Free Survival
MH  - Female
MH  - Genetic Association Studies
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Prognosis
MH  - Receptor, ErbB-2/metabolism
PMC - PMC4498752
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/07/15 06:00
MHDA- 2016/04/09 06:00
PMCR- 2015/07/10
CRDT- 2015/07/11 06:00
PHST- 2015/01/04 00:00 [received]
PHST- 2015/06/19 00:00 [accepted]
PHST- 2015/07/11 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2016/04/09 06:00 [medline]
PHST- 2015/07/10 00:00 [pmc-release]
AID - PONE-D-14-52351 [pii]
AID - 10.1371/journal.pone.0132824 [doi]
PST - epublish
SO  - PLoS One. 2015 Jul 10;10(7):e0132824. doi: 10.1371/journal.pone.0132824. 
      eCollection 2015.